Ausl Ferrara, Italy
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Phase
3Span
201 weeksSponsor
Anthos Therapeutics, Inc.Cinisello Balsamo
Recruiting
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
This is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of anifrolumab versus placebo as added to SOC (consisting of MMF and glucocorticoids) in adults with active proliferative Class III or Class IV LN (both with or without concomitant Class V). The total study duration may be up to approximately 116 weeks, including the Screening and Follow-up. Approximately 360 participants will be randomized in a 1:1 ratio to receive anifrolumab or matching placebo throughout during the Treatment Period.
Phase
3Span
334 weeksSponsor
AstraZenecaCinisello Balsamo
Recruiting
1-2 of 2